The tweet was deleted by the author.
But we saved everything 🙂.
Solid Biosciences has introduced POLARIS-101, a proprietary next-generation muscle-tropic capsid designed to enhance safe, efficient, and scalable delivery of genetic medicines across neuromuscular and cardiac diseases.
The company states that this innovation could transform gene therapy delivery by improving targeting and effectiveness for a broad range of genetic conditions.
View post on X Loading...
Solid Biosciences previously announced plans to present new research on the POLARIS-101 capsid at a leading neuromuscular meeting. The company will also share updates on its INSPIRE DUCHENNE study, according to earlier disclosures. These developments show ongoing efforts to expand the application of gene therapies in neuromuscular disease.